Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;12(3):e1218.
doi: 10.1002/prp2.1218.

Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination

Affiliations
Review

Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination

László G Boros et al. Pharmacol Res Perspect. 2024 Jun.

Abstract

According to the CDC, both Pfizer and Moderna COVID-19 vaccines contain nucleoside-modified messenger RNA (mRNA) encoding the viral spike glycoprotein of severe acute respiratory syndrome caused by corona virus (SARS-CoV-2), administered via intramuscular injections. Despite their worldwide use, very little is known about how nucleoside modifications in mRNA sequences affect their breakdown, transcription and protein synthesis. It was hoped that resident and circulating immune cells attracted to the injection site make copies of the spike protein while the injected mRNA degrades within a few days. It was also originally estimated that recombinant spike proteins generated by mRNA vaccines would persist in the body for a few weeks. In reality, clinical studies now report that modified SARS-CoV-2 mRNA routinely persist up to a month from injection and can be detected in cardiac and skeletal muscle at sites of inflammation and fibrosis, while the recombinant spike protein may persist a little over half a year in blood. Vaccination with 1-methylΨ (pseudouridine enriched) mRNA can elicit cellular immunity to peptide antigens produced by +1 ribosomal frameshifting in major histocompatibility complex-diverse people. The translation of 1-methylΨ mRNA using liquid chromatography tandem mass spectrometry identified nine peptides derived from the mRNA +1 frame. These products impact on off-target host T cell immunity that include increased production of new B cell antigens with far reaching clinical consequences. As an example, a highly significant increase in heart muscle 18-flourodeoxyglucose uptake was detected in vaccinated patients up to half a year (180 days). This review article focuses on medical biochemistry, proteomics and deutenomics principles that explain the persisting spike phenomenon in circulation with organ-related functional damage even in asymptomatic individuals. Proline and hydroxyproline residues emerge as prominent deuterium (heavy hydrogen) binding sites in structural proteins with robust isotopic stability that resists not only enzymatic breakdown, but virtually all (non)-enzymatic cleavage mechanisms known in chemistry.

Keywords: DNA polymerase theta; SARS‐CoV‐2; acid hydrolysis; deutenomics; deuterium; hypoxia; modified mRNA; recombinant spike protein.

PubMed Disclaimer

Conflict of interest statement

Dr. McCullough is the President of the McCullough Foundation and receives no financial support. Dr. McCullough is an advisor to the Truth for Health foundation and receives no financial support. Dr. McCullough is the part‐time Chief Scientific Officer of the Wellness Company and receives salary support and equity position(s). None of these organizations played any role in the development, writing, editing, or review of the manuscript. None of these entities nor Dr. McCullough has a financial stake in the outcome of this manuscript. The other authors have no conflict of interest or financial support to disclose.

Similar articles

Cited by

References

    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384(5):403‐416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316‐1327. doi:10.1016/j.ymthe.2017.03.035 - DOI - PMC - PubMed
    1. Ols S, Yang L, Thompson EA, et al. Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. Cell Rep. 2020;30(12):3964‐3971. doi:10.1016/j.celrep.2020.02.111 - DOI - PMC - PubMed
    1. Krauson AJ, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS‐CoV‐2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;8:141. doi:10.1038/s41541-023-00742-7 - DOI - PMC - PubMed
    1. Brogna C, Cristoni S, Marino G, et al. Detection of recombinant spike protein in the blood of individuals vaccinated against SARS‐CoV‐2: possible molecular mechanisms. Proteomics Clin Appl. 2023;17:e2300048. doi:10.1002/prca.202300048 - DOI - PubMed

MeSH terms